文献速递肝病消化道肿瘤与早癌

直接抗病毒药物不增加局部区域治疗后肝细胞癌复发或肝移植等待名单退出风险

Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
PubMed 文献 · Hepatology · 2018-05-16

这项单中心回顾性队列研究纳入2014至2016年149例丙型肝炎病毒(HCV)合并肝细胞癌(HCC)的肝移植等待者,比较接受与未接受直接抗病毒药物(DAA)治疗者的HCC复发和等待名单退出情况。结果显示,DAA组与非DAA组的HCC复发风险相似,但DAA组因肿瘤进展或死亡的等待名单退出风险更低。

要点

  • 在局部区域治疗完全缓解后1年内,DAA组HCC累积复发率为47.0%,非DAA组为49.8%(P=0.93)。
  • 调整后竞争风险分析中,DAA组HCC复发风险与非DAA组相似(HR 0.91,95%CI 0.58-1.42,P=0.67)。
  • DAA组因肿瘤进展或死亡的等待名单退出风险低于非DAA组(HR 0.30,95%CI 0.13-0.69,P=0.005)。

核心结论

  • 在局部区域治疗初始完全缓解的HCV合并HCC肝移植等待者中,使用DAA与HCC复发风险增加无关,而与因肿瘤进展或死亡导致的等待名单退出风险降低有关。

研究设计与样本

  • 单中心回顾性队列研究,纳入2014年至2016年149例HCV合并HCC的肝移植等待者,其中非DAA组87例、DAA组62例。
  • 采用竞争风险回归评估与结局相关的因素,并使用倾向评分稳定逆概率加权平衡组间基线特征。

主要发现

  • 非DAA组(n=87)肝硬化更严重且局部区域治疗后完全影像学肿瘤缓解率低于DAA组(n=62),但等待名单登记时甲胎蛋白和肿瘤负荷相似。
  • 局部区域治疗完全缓解后1年内HCC累积复发率在DAA组为47.0%,非DAA组为49.8%(P=0.93)。
  • 加权倾向评分模型调整竞争风险分析中,DAA组与非DAA组HCC复发风险相似(HR 0.91,95%CI 0.58-1.42,P=0.67)。
  • 调整加权分析中,DAA组因肿瘤进展或死亡导致的等待名单退出风险低于非DAA组(HR 0.30,95%CI 0.13-0.69,P=0.005)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Whether direct-acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC) recurrence after tumor-directed therapy is controversial. We sought to determine the impact of DAA therapy on HCC recurrence after local-regional therapy (LRT) and waitlist dropout among liver transplant (LT) candidates with HCC. We performed a retrospective cohort study of 149 LT candidates with hepatitis C virus (HCV) and HCC at a single center from 2014 through 2016. Cumulative incidence of HCC recurrence post-LRT and waitlist dropout was estimated by the DAA group. Factors associated with each outcome were evaluated using competing risks regression. A propensity score stabilized inverse probability weighting approach was used to account for differences in baseline characteristics between groups. The no DAA group (n = 87) had more severe cirrhosis and lower rates of complete radiologic tumor response after LRT than those treated with DAA (n = 62) but had similar alpha-fetoprotein and tumor burden at listing. Cumulative incidence of HCC recurrence within 1 year of complete response after LRT was 47.0% in the DAA group and 49.8% in the no DAA group (P = 0.93). In adjusted competing risk analysis using weighted propensity score modeling, risk of HCC recurrence was similar in the DAA group compared to those without DAA (hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.58-1.42; P = 0.67). Patients treated with DAAs had lower risk of waitlist dropout due to tumor progression or death compared to the no DAA group in adjusted weighted analysis (HR, 0.30; 95% CI 0.13-0.69; P = 0.005). CONCLUSION: In LT candidates with HCV and HCC with initial complete response to LRT, DAA use is not associated with increased risk of HCC recurrence but rather is associated with reduced risk of waitlist dropout due to tumor progression or death. (Hepatology 2018).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Huang AC, Mehta N, Dodge JL, et al. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018. PMID: 29476694. doi:10.1002/hep.29855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。